A propensity score matched cohort study identifying an association of acne, but not oral antibiotic or isotretinoin use, with risk of incident inflammatory bowel disease
- PMID: 36682724
- PMCID: PMC10033360
- DOI: 10.1016/j.jaad.2023.01.014
A propensity score matched cohort study identifying an association of acne, but not oral antibiotic or isotretinoin use, with risk of incident inflammatory bowel disease
Abstract
Background: Concerns remain regarding whether oral antibiotic or isotretinoin use for acne is associated with increased risk of inflammatory bowel disease (IBD); little is known about whether acne itself is associated with IBD.
Objective: To determine whether isotretinoin exposure, oral tetracycline-class antibiotic exposure, and/or acne itself are associated with IBD.
Methods: A propensity score matched cohort study was performed using TriNetX between 2001 and 2022 to compare the 1-year incidence of IBD between those without acne compared to those with acne managed without systemic medications, acne managed with oral tetracycline-class antibiotics, and acne managed with isotretinoin.
Results: There was a statistically significant association between acne and risk of incident IBD (odds ratio: 1.42; 95% confidence interval: 1.23-1.65). There was no statistically significant association between oral tetracycline-class antibiotic or isotretinoin exposure and IBD.
Limitations: Use of electronic health data; potential for misclassification bias.
Conclusion: This matched cohort study identifies an association between acne and IBD. These data provide further reassurance regarding the use of isotretinoin in the treatment of acne.
Keywords: Crohn's disease; acne; doxycycline; inflammatory bowel disease; isotretinoin; minocycline; tetracyclines; ulcerative colitis.
Copyright © 2023 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest Dr Kwatra is an advisory board member/consultant for Abbvie, Aslan Pharmaceuticals, Arcutis Biotherapeutics, Castle Biosciences, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. Taylor, Margolis, and Barbieri have no conflicts of interest to declare.
Similar articles
-
Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease.Am J Gastroenterol. 2010 Dec;105(12):2610-6. doi: 10.1038/ajg.2010.303. Epub 2010 Aug 10. Am J Gastroenterol. 2010. PMID: 20700115
-
Isotretinoin and risk of inflammatory bowel disease: More data to support lack of meaningful risk.J Am Acad Dermatol. 2021 Jan;84(1):228-229. doi: 10.1016/j.jaad.2020.07.041. Epub 2020 Jul 17. J Am Acad Dermatol. 2021. PMID: 32682880 No abstract available.
-
Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study.J Invest Dermatol. 2013 Apr;133(4):907-12. doi: 10.1038/jid.2012.387. Epub 2012 Oct 25. J Invest Dermatol. 2013. PMID: 23096714 Free PMC article.
-
Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis.Eur J Gastroenterol Hepatol. 2016 Feb;28(2):210-6. doi: 10.1097/MEG.0000000000000496. Eur J Gastroenterol Hepatol. 2016. PMID: 26545085 Review.
-
Concomitant antibiotic usage does not augment the risk of inflammatory bowel disease with isotretinoin treatment for acne: a review of the Food and Drug Administration Adverse Event Reporting System.Eur J Clin Pharmacol. 2013 Apr;69(4):1041-2. doi: 10.1007/s00228-012-1416-1. Epub 2012 Oct 6. Eur J Clin Pharmacol. 2013. PMID: 23052415 Review. No abstract available.
Cited by
-
Do Antibiotics Cause Inflammatory Bowel Disease? A Systematic Review and Meta-Analysis.Visc Med. 2025 Feb;41(1):32-47. doi: 10.1159/000541601. Epub 2024 Oct 23. Visc Med. 2025. PMID: 39927188 Review.
-
Authors' Reply to Chen and Chen: Comment on: "Isotretinoin Exposure and Risk of Inflammatory Bowel Disease: A Systematic Review with Meta-Analysis and Trial Sequential Analysis".Am J Clin Dermatol. 2023 Sep;24(5):855-858. doi: 10.1007/s40257-023-00803-6. Epub 2023 Jun 27. Am J Clin Dermatol. 2023. PMID: 38036748 No abstract available.
-
A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX.Front Pharmacol. 2025 Mar 10;16:1516126. doi: 10.3389/fphar.2025.1516126. eCollection 2025. Front Pharmacol. 2025. PMID: 40129946 Free PMC article. Review.
References
-
- Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–973.e33. - PubMed
-
- Barbieri JS, James WD, Margolis DJ. Trends in prescribing behavior of systemic agents used in the treatment of acne among dermatologists and nondermatologists: A retrospective analysis, 2004–2013. J Am Acad Dermatol. 2017;77(3):456–463.e4. - PubMed
-
- Lee SY, Jamal MM, Nguyen ET, Bechtold ML, Nguyen DL. Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis. Eur J Gastroenterol Hepatol. 2016;28(2):210–216. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical